Effect of S9788 on the efficiency of doxorubicin in vivo and in vitro in medullary thyroid carcinoma renegraft

Anti-Cancer Drugs

Volumn 7, Issue 3, 1996, Pages 321-330

  Massart, C ^a   Gibassier, J ^a   Raoul, M ^a   Denais, A ^a   Maugendre, S ^a   Darcel, F ^a   Lucas, C ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

Doxorubicin; Glycoprotein P 170; Medullary carcinoma; Nude mice; S9788; Thyroid

Indexed keywords

2,4 BIS(ALLYLAMINO) 6 [4 [[2,2 BIS(4 FLUOROPHENYL)ETHYL]AMINO]PIPERIDINO] 1,3,5 TRIAZINE; DOXORUBICIN; GLYCOPROTEIN P;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG RESISTANCE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; THYROID MEDULLARY CARCINOMA; TUMOR CELL LINE; TUMOR XENOGRAFT;

EID: 0029941263     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199605000-00013     Document Type: Article

References (33)

1. Schlumberger M, Gardet P, de Vataire F, et al. External radiotherapy and chemotherapy in MTC patients. In: Camettes C, Guliana JM, eds. Medullary thyroid carcinoma. Colloque INSERM/John Libbey Eurotext: Paris 1991: 213-20.
2. Leong SS, Horoszewicz JS, Shimaoka K, et al. A new cell line for study of human medullary thyroid carcinoma. In: Andreoli M, Monaco F, Robbins J, eds. Advances in thyroid neoplasia. Rome: Fied Educational Italia 1981: 95-108.
3. Massart C, Gibassier J, Giscard-Dartevelle S, et al. Etude hormonale de deux cas de cancer mixte médullaire et folliculaire de la thyroïde. Ann Endocrinol 1993; 54: 67.
4. Massart C, Gibassier J, Lucas C, et al. Hormonal study of a mixed follicular and medullary carcinoma. J Mol Endocrinol 1993; 11; 59-67.
5. Larsson R, Nygren P. Verapamil and cyclosporin A potentiate the effects of chemotherapeutic drugs in the human medullary thyroid carcinoma TT cell line not expressing the 170 kDa P-glycoprotein. Cancer Lett 1990; 54: 125-31.
6. Massart C, Gibassier J, Raoul ML, et al. Cyclosporin A, verapamil and S9788 reverse doxorubicin resistance in a human medullary thyroid carcinoma cell line. Anti-Cancer Drugs 1995; 6: 135-46.
7. Massart C, Gibassier J, Lucas C, Pourquier P, Robert J. Expression du gène MDR1 dans 5 lignées humaines de cancer médullaire de la thyroìde et réversion de la résistance à la doxorubicine par la ciclosporine A et le vérapamil. Bull Cancer 1996; 83: 39-45
8. Yang KP, Liang YF, Samaan NA. Intrinsic drug resistance in a human medullary thyroid carcinoma cell line: association with over expression of mdr1 gene and low proliferation fraction. Anticancer Res 1991; 11: 1065-68.
9. Akiyama SI, Fojo A, Hanover JA, Pastan I, Gottesman MM. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet 1985; 11: 117-26.
10. Batist G, Tulpule A, Sinha BK, et al. Over expression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 1986; 261: 15544-9.
11. Dhainaut A, Regnier G, Attasi G, et al. New triazine derivatives as potent modulators of multi-drug resistance. J Med Chem 1992; 35: 2481-96.
12. Leonce S, Pierre A, Anstett M, et al. Effects of a new triazinoaminopiperidine derivative on adriamycin accumulation and retention in cells displaying P-glycoprotein-mediated multidrug resistance. Biochem Pharmacol 1992; 44: 1707-15.
13. Bennis S, Robert J. Effets differentiels du S9788, du vérapamil et de la quinine sur la réversion de la multidrug resistance dans deux lignées tumorales humaines. Bull Cancer 1994; 8: 886-90.
14. Efferth T, Dunn TA, Berlion M, Langenbahn H, Pommerenke EW, Volm M. Reversal of inherent multidrug-resistance in primary human renal cell carcinoma cell cultures by S9788. Anticancer Res 1993; 13: 905-8.
15. GPCO. Propriétés pharmacologiques du S9788, un nouvel agent modulateur de la résistance pléiotropique. Bull Cancer 81; 93-103.
16. Julia AM, Roché H, Berlion M, Lucas C, et al. Multidrug resistance circumvention by a new triazinoaminopiperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamil. Br J Cancer 1994; 69: 868-74.
17. Hill BT, Van Der Graaf WTA, Hosking LK, et al. Evaluation of S9788 as a potential modulator of drug resistance against human tumour subline expressing differing resistance mechanisms in vitro. Int J Cancer 1993; 55: 330-7.
18. Pfragner R, Höfler H, Behme A, Ingolic H, Walser V. Establishment and characterization of continuous cell line MTC-SK derived from a human medullary thyroid carcinoma. Cancer Res 1990; 50: 4160-6.
19. Chu TM, Kawinski E, Lin TH. Characterization of a new monoclonal antibody E4 detecting cell surface epitope and P-glycoprotein in drug-resistant human tumor cell lines. In: Liebert MA, ed. Hybridoma. Inc Publishers 1993; 12: 4.
20. Oudard S, Poupon MF. La résistance multidrogue. Bull Cancer 1993; 13s-20s.
21. Van der Valk P, Van Kalken CK, Ketelaars H, et al., Distribution of multi-drug resistance-associated P-glycoprotein in normal and neoplastic human tissues. Ann Oncol 1990; 1: 56-64.
22. Vergier B, Cany L, Bonnet F, Robert J, De Mascarel A, Coindre JM. Expression of MDR1/P glycoprotein in human sarcomas. Br J Cancer 1993; 68; 1221-6.
23. Müller MR, Lennartz K, Nowrousian MR, et al. Improved flow-cytometric detection of low P-glycoprotein expression in leukaemic blasts by histogram subtraction analysis. Cytometry 1994; 15: 64-72.
24. Krishan A, Ganapathi R. Laser flow cytometric studies on the intracellular fluorescence of anthracyclines. Cancer Res 1980; 40: 3895-900.
25. Ramachandran C, Sauerteig A, Sridhar KS, Thurer RJ, Krishan A. MDR-1 gene expression, anthracycline retention and cytotoxicity in human lung-tumor cells from refractory patients. Cancer Chemother Pharmacol 1993; 31: 431-41.
26. Tanaka S, Aizawa K, Katayanagi N, Tanaka O. Flow cytometric analysis of early steps in development of adriamycin in a human gastric cancer cell line. Jpn J Res 1994; 85; 86-92.
27. Kobayashi Y, Yamashiro T, Nagatake H, et al. Expression and function of multidrug resistance P-glycoprotein in a cultured natural killer cell-rich population revealed by MRK 16 monoclonal antibody and AHC-52. Biochem Pharmacol 1994; 48: 1641-46.
28. Merlin JL, Guerci A, Marchai S, et al. Comparative evaluation of S9788, verapamil and cyclosporin A in K562 human leukemia cell lines and in P-glycoprotein-expressing samples from patients with hematologic malignancies. Blood 1994; 84: 262-9.
29. Takeshita A, Shinjo K, Ohnishi K, Ohno R. New flow cytometric method for detection of minimal expressed multidrug resistance P-glycoprotein on normal and acute leukemia cells using biotinylated MRK16 and streptavidin-RED670 conjugate. Jpn J Cancer Res 1995; 86: 607-15.
30. Van Acker KL, Van Hove LM, Boogaerts MA. Evaluation of flow cytometry for multidrug resistance detection in low resistance K562 cells using daunorubicin and monoclonal antibodies. Cytometry 1993; 14: 736-46.
31. Feller N, Kuiper CM, Lankelma, et al. Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry. Br J Cancer 1995; 72: 513-9.
32. Twentyman PR, Rhodes T, Rayner S. A comparison of rhodamine 123 accumulation and efflux in cells with P-glycoprotein-mediated and MRP-associated multidrug resistance phenotypes. Eur J Cancer 1994; 30A: 1360-69.
33. Childs S, Lin Yeh R, Georges E, Ling V. Identification of a Sister gene to P-glycoprotein. Cancer Res 1995; 55: 2029-34.